Pharmaceutical company Morepen Laboratories Ltd on Monday (March 17) said it has launched a new treatment for Type 2 diabetes, heart failure, and chronic kidney disease. The drug, Empamore, is said to provide an affordable and high-quality alternative to existing treatments for millions of patients in India.Empamore contains empagliflozin and is available in multiple formulations, including 10mg and 25mg doses, as well as combination variants with metformin (500mg/1000mg). Morepen manufactures empagliflozin at its USFDA-approved facilities and holds a European Drug Master File (DMF), ensuring global-quality standards.
Also Read: Morepen Laboratories to hive off medical devices business to subsidiary Morepen Medtech
Empagliflozin is widely used for diabetes management. Prediabetes cases in India have risen to nearly 136 million, and the diabetes market is expected to grow at a compounded annual rate of 10.9%,Ashutosh Sharma, Vice President of sales & marketing at Morepen Laboratories, said, “With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without financial strain.”
Shares of Morepen Laboratories Ltd ended at ₹42.80, down by ₹1.86, or 4.16%, on the BSE.
Also Read: Morepen Laboratories launches QIP to raise up to ₹200 crore
